| Company Name |
Innovacell GmbH
|
| Head office |
Mitterweg 24, 6020 Innsbruck, Austria
|
| Contact |
Tel: +43 (0)512 573680
Email Address: office@innovacell.com
|
| What we do |
- Innovacell is a biotechnology company focused on developing, producing and marketing cell therapies for treating fecal and urinary incontinence. Technologies for isolating, multiplying, using and delivering muscle cells have been developed. Associated patents have already been granted or their applications filed.
- Innovacell works according to the rules of “Good Laboratory Practice” (GLP), “Good Manufacturing Practice” (GMP) and “Good Clinical Practice” (GCP). These guidelines ensure that internationally recognized quality standards are met while developing, manufacturing, processing, packaging and storing pharmaceuticals and that customers and patients receive products of the highest quality.
- Innovacell is one of the largest producers of autologous (endogenous) in vitro multiplied cells in Europe.
- Innovacell has approval to manufacture cell therapy test material for clinical studies. This includes currently the following cell types: autologous skeletal muscle cells, skin fibroblasts, and hair follicle cells.
- Innovacell aims to market the products it has developed in the five key European countries (Germany, France, Italy, Spain and the United Kingdom) as well as in Japan and the USA. The goal is to become a global leader in the field of regenerative medicine with a focus on innovative, personalized cell therapies.
|
| Commercial Register Number / Competent Court |
FN 545280h / Landesgericht Innsbruck
|
| Supervisory Authority |
BASG (Bundesamt für Sicherheit im Gesundheitswesen)
|
| Chamber Membership |
Wirtschaftskammer Tirol (Membership No. 473499)
|
| Applicable Professional or Trade Regulations |
Gewerbeordnung (GewO)
|
| VAT Identification Number (UID) |
ATU76336706
|
| Business Activities |
Development, manufacturing, and sale of cell therapies for the treatment of fecal and urinary incontinence
|
| Authorized Representatives |
- Dr. Rainer Marksteiner
- Colin Lee Novick
- Jason David Sieger
- Yasushi Hosono
|
| Shareholder |
Innovacell Inc. (100%), located and registered in Japan
|
| Editorial Policy |
This website provides information about the company and its activities in the field of cell therapy.
|